Dianthus reports FY2023 net loss $43.6M, cash $389M; Phase 2 gMG trial initiated

Dianthus Therapeutics, Inc. /DE/

FY2023 net loss $43.6M ($8.45/share), R&D $32.8M, G&A $18.2M.
Pro forma cash $389M (including $216M net from Jan 2024 PIPE); runway to 2H 2027.
Phase 2 MaGic gMG trial initiated Feb 2024; top-line data expected 2H 2025.
Phase 2 trials planned: MMN (Q2 2024) and CIDP (2H 2024).
Jeffrey Stavenhagen appointed CSO in Nov 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ reported the year ended December 31, 2023 results: net income $43.6 million, EPS $8.45 net loss per share (basic and diluted).

Period: the year ended December 31, 2023
Net income: $43.6 million
EPS: $8.45 net loss per share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted)

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-24-034667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.